What is Zacks Research’s Estimate for ALNY FY2024 Earnings?

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) – Investment analysts at Zacks Research increased their FY2024 earnings per share (EPS) estimates for Alnylam Pharmaceuticals in a report issued on Wednesday, November 20th. Zacks Research analyst A. Chakraborty now forecasts that the biopharmaceutical company will post earnings per share of ($2.52) for the year, up from their prior forecast of ($2.65). The consensus estimate for Alnylam Pharmaceuticals’ current full-year earnings is ($2.21) per share. Zacks Research also issued estimates for Alnylam Pharmaceuticals’ Q4 2024 earnings at ($1.00) EPS, Q1 2025 earnings at ($0.95) EPS, Q2 2025 earnings at ($0.96) EPS, Q4 2025 earnings at ($0.53) EPS, FY2025 earnings at ($3.26) EPS, Q1 2026 earnings at $0.33 EPS, Q2 2026 earnings at $0.09 EPS, Q3 2026 earnings at $0.64 EPS and FY2026 earnings at $1.71 EPS.

A number of other equities research analysts also recently weighed in on ALNY. Wells Fargo & Company lifted their target price on Alnylam Pharmaceuticals from $207.00 to $233.00 and gave the stock an “equal weight” rating in a research report on Friday, August 2nd. Barclays raised their price target on shares of Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the stock an “overweight” rating in a research note on Friday, November 1st. Canaccord Genuity Group raised their price target on shares of Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the stock a “buy” rating in a research note on Friday, November 1st. TD Cowen raised their price target on shares of Alnylam Pharmaceuticals from $282.00 to $371.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. Finally, Piper Sandler restated an “overweight” rating and set a $296.00 price target on shares of Alnylam Pharmaceuticals in a research note on Monday, November 18th. One research analyst has rated the stock with a sell rating, five have given a hold rating and nineteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Alnylam Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $298.09.

Alnylam Pharmaceuticals Stock Up 0.9 %

ALNY stock opened at $253.35 on Monday. Alnylam Pharmaceuticals has a twelve month low of $141.98 and a twelve month high of $304.39. The company has a market cap of $32.68 billion, a PE ratio of -96.70 and a beta of 0.39. The business’s 50-day simple moving average is $272.74 and its 200 day simple moving average is $239.37. The company has a quick ratio of 2.69, a current ratio of 2.75 and a debt-to-equity ratio of 31.64.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The company had revenue of $500.90 million during the quarter, compared to analyst estimates of $532.91 million. During the same quarter in the previous year, the business posted $1.15 earnings per share. The firm’s quarterly revenue was down 33.3% compared to the same quarter last year.

Institutional Trading of Alnylam Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the business. Ashton Thomas Private Wealth LLC bought a new stake in shares of Alnylam Pharmaceuticals during the 2nd quarter valued at $26,000. Huntington National Bank raised its position in shares of Alnylam Pharmaceuticals by 91.8% during the 3rd quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 45 shares during the last quarter. Hollencrest Capital Management bought a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at $29,000. Washington Trust Advisors Inc. bought a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at $42,000. Finally, True Wealth Design LLC increased its position in shares of Alnylam Pharmaceuticals by 15,300.0% in the 3rd quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company’s stock valued at $42,000 after buying an additional 153 shares in the last quarter. Institutional investors own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.